PPCB
Propanc Biopharma, Inc.
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
$1.47
▲ 0.00%$1.47▼ -98.53%
over 1Y
L $1.35EODHDH $260.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-0.7%
1M-9.3%
3M-43.0%
YTD-89.7%
1Y-98.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.41x).
Propanc Biopharma, Inc. shows limited reported revenue, and -423.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$1.81M | -$1.99M | -$1.78M | -$1.54M | -$57.3M |
| Net income | -$2.03M | -$2.66M | -$2.66M | -$1.82M | -$58.9M |
| Diluted EPS | — | -$49.23 | -$1.80 | -$1,420.53 | -$14.85 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$19.4M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-313.0%
FCF yield-2.2%
Quality & risk
ROIC (est.)-313.3%
Free cash flow-$408K
Total debt$538K
Net cash-$534K
Piotroski F-Score5/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-98.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-01-07). Worth a closer look.
- 10-Q Quarterly report2026-05-14
- S-1 Securities registration2026-04-10
- 8-K Officer / director change2026-02-26
- S-1/A Securities registration2026-02-19
- 10-Q Quarterly report2026-02-17
- S-1 Securities registration2026-02-02
- 8-K Delisting notice2026-01-07
- S-1 Securities registration2025-12-30
- 10-Q Quarterly report2025-11-14
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-14open ↗EFFECTFiling2026-04-20open ↗CORRESPFiling2026-04-16open ↗UPLOADFiling2026-04-15open ↗S-1Filing2026-04-10open ↗DEF 14CPeriod ending 2026-03-312026-03-31open ↗PRE 14CPeriod ending 2026-03-192026-03-20open ↗PRE 14APeriod ending 2026-03-192026-03-19open ↗424B3Filing2026-03-06open ↗8-KPeriod ending 2026-02-202026-02-26open ↗EFFECTFiling2026-02-24open ↗CORRESPFiling2026-02-20open ↗
Frequently asked
- Is Propanc Biopharma, Inc. (PPCB) a buy?
- PPCB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.41x).
- What is Propanc Biopharma, Inc.'s quality score?
- PPCB scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001517681, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:48:33 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.